RVTY vs BIO vs TMO vs WAT

For growth investors, Waters Corporation (WAT) is the stronger pick with 7.

0% revenue growth year-over-year, versus 0. 7% for Bio-Rad Laboratories, Inc. (BIO). Bio-Rad Laboratories, Inc. (BIO) offers the better valuation at 9. 2x trailing P/E (25. 0x forward), making it the more compelling value choice. Analysts rate Revvity, Inc. (RVTY) a "Buy" — based on 29 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

On trailing P/E, Bio-Rad Laboratories, Inc.

(BIO) is the cheapest at 9. 2x versus Revvity, Inc. at 47. 5x. On forward P/E, Revvity, Inc. is actually cheaper at 18. 3x — notably different from the trailing picture, reflecting expected earnings growth. The PEG ratio (P/E divided by earnings growth rate) is the most growth-adjusted single valuation metric: Waters Corporation wins at 4. 70x versus Thermo Fisher Scientific Inc. 's 9. 05x.

Over the past 5 years, Waters Corporation (WAT) delivered a total return of +11.

3%, compared to -57. 7% for Bio-Rad Laboratories, Inc. (BIO). Over 10 years, the gap is even starker: TMO returned +229. 1% versus BIO's +81. 4%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

By beta (market sensitivity over 5 years), Bio-Rad Laboratories, Inc.

(BIO) is the lower-risk stock at 0. 92β versus Revvity, Inc. 's 1. 57β — meaning RVTY is approximately 70% more volatile than BIO relative to the S&P 500. On balance sheet safety, Bio-Rad Laboratories, Inc. (BIO) carries a lower debt/equity ratio of 21% versus 76% for Thermo Fisher Scientific Inc. — giving it more financial flexibility in a downturn.

By revenue growth (latest reported year), Waters Corporation (WAT) is pulling ahead at 7.

0% versus 0. 7% for Bio-Rad Laboratories, Inc. (BIO). On earnings-per-share growth, the picture is similar: Bio-Rad Laboratories, Inc. grew EPS 142. 6% year-over-year, compared to -13. 7% for Revvity, Inc.. Over a 3-year CAGR, WAT leads at 2. 1% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

Bio-Rad Laboratories, Inc.

(BIO) is the more profitable company, earning 29. 4% net margin versus 8. 5% for Revvity, Inc. — meaning it keeps 29. 4% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: WAT leads at 28. 2% versus 10. 5% for BIO. At the gross margin level — before operating expenses — WAT leads at 57. 8%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

The PEG ratio (forward P/E divided by expected earnings growth rate) is the most precise measure of undervaluation relative to growth potential.

By this metric, Waters Corporation (WAT) is the more undervalued stock at a PEG of 4. 70x versus Thermo Fisher Scientific Inc. 's 9. 05x. Both stocks trade at elevated growth-adjusted valuations, so expected growth needs to materialise. On forward earnings alone, Revvity, Inc. (RVTY) trades at 18. 3x forward P/E versus 25. 0x for Bio-Rad Laboratories, Inc. — 6. 7x cheaper on a one-year earnings basis. Analyst consensus price targets imply the most upside for TMO: 38. 0% to $654. 67.

In this comparison, TMO (0.

4% yield), RVTY (0. 3% yield) pay a dividend. BIO, WAT do not pay a meaningful dividend and should not be held primarily for income.

For long-horizon retirement investors, Bio-Rad Laboratories, Inc.

(BIO) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0. 92)). Revvity, Inc. (RVTY) carries a higher beta of 1. 57 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Both have compounded well over 10 years (BIO: +81. 4%, RVTY: +88. 4%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.

In terms of investment character: RVTY is a mid-cap quality compounder stock; BIO is a small-cap deep-value stock; TMO is a mid-cap quality compounder stock; WAT is a mid-cap quality compounder stock. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.